Edgewise Therapeutics (EWTX) Change in Account Payables (2020 - 2026)

Edgewise Therapeutics has disclosed Change in Account Payables across 7 years of filings, most recently posting $1.4 million for Q1 2026.

• Change in Account Payables for Q1 2026 came in at $1.4 million, down 49.41% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.1 million (down 129.88% YoY), and the FY2025 annual result was $272000.0, down 84.34% from the prior year.
• Change in Account Payables came in at $1.4 million for Q1 2026 at Edgewise Therapeutics, up from -$303000.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $2.9 million in Q1 2025 to a low of -$2.7 million in Q2 2022.
• The 5-year median for Change in Account Payables is $92000.0 (2024), against an average of $200588.2.
• Across the five-year window, Change in Account Payables surged 1985.71% in 2022 and plunged 429.35% in 2025, its largest moves.
• Edgewise Therapeutics' Change in Account Payables stood at $576000.0 in 2022, then plunged by 339.93% to -$1.4 million in 2023, then soared by 106.66% to $92000.0 in 2024, then slumped by 429.35% to -$303000.0 in 2025, then soared by 577.23% to $1.4 million in 2026.
• The last three Change in Account Payables figures came in at $1.4 million (Q1 2026), -$303000.0 (Q4 2025), and -$2.1 million (Q3 2025), per Business Quant data.